Tisagenlecleucel Infusion Suppliers & Bulk Manufacturers

Available Forms: IV Infusion

Available Strengths: Single infusion, approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL)

Reference Brands: Kymriah(US & EU)

Category: Cell & Gene Therapies

Tisagenlecleucel is a CAR T-cell therapy that reprograms a patient's T cells to target and destroy CD19-positive cancer cells. It offers targeted treatment for refractory B-cell cancers, providing rapid remission, improved survival rates, and the potential for long-term disease control in leukemia and lymphoma patients when administered in specialized centers.

Product Description:

Tisagenlecleucel (Kymriah) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality according to GMP and MDR standards. In the US, FDA approval involves extensive clinical validation for refractory B-cell malignancies, including safety monitoring. In the EU, CE marking certifies conformity with MDR regulations. These CAR T-cell therapies undergo validation, stability testing, and rigorous audits, with detailed documentation including clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to innovative, effective immunotherapies supporting advanced cancer treatment worldwide.